English

Blueprint Medicines Corporation

EDGAR

BPMC Quarterly report (10-Q) · filed 2025-05-01

170 filing records in this dataset, filed from 2015-03-23 to 2025-05-01. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

954 thousand Unit1

2018 Q1 · Unit1

Exact inputs and evidence

Revenue: 954000 Unit1 Source

Cash and cash equivalents: 122 million Unit_Standard_USD_t7FwWv25MUiKY2FqSZlAgw 2025-03-31 Source
Exact value

122245000 Unit_Standard_USD_t7FwWv25MUiKY2FqSZlAgw
Long-term debt including current maturities: 1.53 million Unit1 2017-12-31 Source
Exact value

1528000 Unit1
Shares outstanding: 64.6 million Unit_Standard_shares_TEX7w2SlFkOY85sS5_2Prg 2025-03-31 Source
Exact value

64563911 Unit_Standard_shares_TEX7w2SlFkOY85sS5_2Prg

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

16.5 million Unit1

2017-04-01 – 2018-03-31

Exact inputs and evidence

Revenue: 5890000 Unit1 · 2017-04-01 – 2017-06-30 Source
Revenue: 8068000 Unit1 · 2017-07-01 – 2017-09-30 Source
Revenue: 1628000 Unit1 · 2017-10-01 – 2017-12-31 Source
Revenue: 954000 Unit1 · 2018-01-01 – 2018-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2025-05-01.

Financial data available through: 2024-12-31.

Coverage by financial measure

Revenue: 3 of 11 periods available· newest 2017-12-31
operating income: No compatible figures in this window
Net income: 3 of 11 periods available· newest 2024-12-31
Operating cash flow: 3 of 11 periods available· newest 2024-12-31
Capital expenditure: 3 of 11 periods available· newest 2024-12-31
Total assets: Multiple units; comparison withheld· newest 2024-12-31
Total liabilities: Multiple units; comparison withheld· newest 2024-12-31
Current assets: Multiple units; comparison withheld· newest 2024-12-31
Current liabilities: Multiple units; comparison withheld· newest 2024-12-31
Cash and cash equivalents: Multiple units; comparison withheld· newest 2024-12-31
Long-term debt including current maturities: 1 of 11 periods available· newest 2017-12-31
Shares outstanding: Multiple units; comparison withheld· newest 2024-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Net income
+Unit_Standard_USD_J14XWe-4AE6YifluMea2JA 439.9 million

Prior period

−Unit_Standard_USD_J14XWe-4AE6YifluMea2JA 506.98 million

2023-01-01 – 2023-12-31
Current period

−Unit_Standard_USD_J14XWe-4AE6YifluMea2JA 67.09 million

2024-01-01 – 2024-12-31

Exact inputs and evidence

-67089000 − -506984000 = 439895000 Unit_Standard_USD_J14XWe-4AE6YifluMea2JA

-506984000 Unit_Standard_USD_J14XWe-4AE6YifluMea2JA · 2023-01-01 – 2023-12-31
Inspect prior input Prior source
-67089000 Unit_Standard_USD_J14XWe-4AE6YifluMea2JA · 2024-01-01 – 2024-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Blueprint Medicines Corporation · 2024-12-31 Blueprint Medicines Corporation (edgar:1597264) Year-over-year change in Net income: 439895000 Unit_Standard_USD_J14XWe-4AE6YifluMea2JA Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T13:49:12Z Snapshot: 4f0576df741ca9ce99a0a19b182da607af576553123ebb31b0ca4530075f302a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1597264?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -67089000 Unit_Standard_USD_J14XWe-4AE6YifluMea2JA (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1597264/000155837025000953/bpmc-20241231x10k.htm#3858477 Filing: 000155837025000953 Input fundies:NetIncome: -506984000 Unit_Standard_USD_J14XWe-4AE6YifluMea2JA (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1597264/000155837025000953/bpmc-20241231x10k.htm#3859554 Filing: 000155837025000953
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+Unit_Standard_USD_J14XWe-4AE6YifluMea2JA 244.26 million

Prior period

−Unit_Standard_USD_J14XWe-4AE6YifluMea2JA 436.85 million

2023-01-01 – 2023-12-31
Current period

−Unit_Standard_USD_J14XWe-4AE6YifluMea2JA 192.59 million

2024-01-01 – 2024-12-31

Exact inputs and evidence

-192586000 − -436847000 = 244261000 Unit_Standard_USD_J14XWe-4AE6YifluMea2JA

-436847000 Unit_Standard_USD_J14XWe-4AE6YifluMea2JA · 2023-01-01 – 2023-12-31
Inspect prior input Prior source
-192586000 Unit_Standard_USD_J14XWe-4AE6YifluMea2JA · 2024-01-01 – 2024-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Blueprint Medicines Corporation · 2024-12-31 Blueprint Medicines Corporation (edgar:1597264) Year-over-year change in Operating cash flow: 244261000 Unit_Standard_USD_J14XWe-4AE6YifluMea2JA Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T13:49:12Z Snapshot: 4f0576df741ca9ce99a0a19b182da607af576553123ebb31b0ca4530075f302a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1597264?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -192586000 Unit_Standard_USD_J14XWe-4AE6YifluMea2JA (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1597264/000155837025000953/bpmc-20241231x10k.htm#2333991 Filing: 000155837025000953 Input fundies:OperatingCashFlow: -436847000 Unit_Standard_USD_J14XWe-4AE6YifluMea2JA (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1597264/000155837025000953/bpmc-20241231x10k.htm#2335091 Filing: 000155837025000953
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-71.2%

Prior period

Unit_Standard_USD_J14XWe-4AE6YifluMea2JA 16.06 million

2023-01-01 – 2023-12-31
Current period

Unit_Standard_USD_J14XWe-4AE6YifluMea2JA 4.63 million

2024-01-01 – 2024-12-31

Exact inputs and evidence

4630000 − 16062000 = -11432000 Unit_Standard_USD_J14XWe-4AE6YifluMea2JA

16062000 Unit_Standard_USD_J14XWe-4AE6YifluMea2JA · 2023-01-01 – 2023-12-31
Inspect prior input Prior source
4630000 Unit_Standard_USD_J14XWe-4AE6YifluMea2JA · 2024-01-01 – 2024-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Blueprint Medicines Corporation · 2024-12-31 Blueprint Medicines Corporation (edgar:1597264) Year-over-year change in Capital expenditure: -11432000 Unit_Standard_USD_J14XWe-4AE6YifluMea2JA Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T13:49:12Z Snapshot: 4f0576df741ca9ce99a0a19b182da607af576553123ebb31b0ca4530075f302a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1597264?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 4630000 Unit_Standard_USD_J14XWe-4AE6YifluMea2JA (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1597264/000155837025000953/bpmc-20241231x10k.htm#2340016 Filing: 000155837025000953 Input fundies:CapitalExpenditure: 16062000 Unit_Standard_USD_J14XWe-4AE6YifluMea2JA (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1597264/000155837025000953/bpmc-20241231x10k.htm#2341105 Filing: 000155837025000953
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Revenue.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2017 2017-01-01 – 2017-12-31

Revenue Unit1 21.43 million 100% of revenue
Operating costs Derived Unavailable An input is unavailable.
Operating income Unavailable An input is unavailable.
Tax, interest and other Derived Unavailable An input is unavailable.
Net income Unavailable An input is unavailable.

Cash

Operating cash flow Unavailable An input is unavailable.
Capital expenditure Unavailable An input is unavailable.
Free cash flow Derived Unavailable An input is unavailable.

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2015 Not shown: operating income or net income is not reported.
2016 Not shown: operating income or net income is not reported.
2017 Not shown: operating income or net income is not reported.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2015 2015-01-01 – 2015-12-31	11400000	Unavailable	Unavailable	Unavailable	Unavailable	Unavailable	Source 2015-01-01 – 2015-12-31: 11400000 Unit1 Inspect Revenue Open source
2016 2016-01-01 – 2016-12-31	27772000	Unavailable	Unavailable	Unavailable	Unavailable	Unavailable	Source 2016-01-01 – 2016-12-31: 27772000 Unit1 Inspect Revenue Open source
2017 2017-01-01 – 2017-12-31	21426000	Unavailable	Unavailable	Unavailable	Unavailable	Unavailable	Source 2017-01-01 – 2017-12-31: 21426000 Unit1 Inspect Revenue Open source

Amounts are exact, in Unit1.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

Unit1 21.4M 2017

Values and sources

Revenue values and source evidence
Period	Series	Value(Unit1)	Source evidence
20152015-12-31	Revenue	11400000	Revenue: 11400000 Open source
20162016-12-31	Revenue	27772000	Revenue: 27772000 Open source
20172017-12-31	Revenue	21426000	Revenue: 21426000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-22.9% 2017

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20152015-12-31	Year over year	No prior comparable period	Revenue: 11400000 Open source
20162016-12-31	Year over year	143.6%	Revenue: 27772000 Open source Revenue: 11400000 Open source
20172017-12-31	Year over year	-22.9%	Revenue: 21426000 Open source Revenue: 27772000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Not enough comparable data to show this history.

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
2015-12-31	Operating margin	Not reported	Revenue: 11400000 Open source
2016-12-31	Operating margin	Not reported	Revenue: 27772000 Open source
2017-12-31	Operating margin	Not reported	Revenue: 21426000 Open source
2015-12-31	Net margin	Not reported	Revenue: 11400000 Open source
2016-12-31	Net margin	Not reported	Revenue: 27772000 Open source
2017-12-31	Net margin	Not reported	Revenue: 21426000 Open source
20152015-12-31	Free cash flow margin	Not reported	Revenue: 11400000 Open source
20162016-12-31	Free cash flow margin	Not reported	Revenue: 27772000 Open source
20172017-12-31	Free cash flow margin	Not reported	Revenue: 21426000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

Not enough comparable data to show this history.

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(Unit1)	Source evidence
20152015-12-31	Operating cash flow	Not reported	No source recorded
20162016-12-31	Operating cash flow	Not reported	No source recorded
20172017-12-31	Operating cash flow	Not reported	No source recorded

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

Not enough comparable data to show this history.

Values and sources

Free cash flow values and source evidence
Period	Series	Value	Source evidence
20152015-12-31	Free cash flow	Unavailable	No source recorded
20162016-12-31	Free cash flow	Unavailable	No source recorded
20172017-12-31	Free cash flow	Unavailable	No source recorded

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

Not enough comparable data to show this history.

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2015-12-31	Liabilities / assets	Not reported	No source recorded
2016-12-31	Liabilities / assets	Not reported	No source recorded
2017-12-31	Liabilities / assets	Not reported	No source recorded

Current assets to current liabilities

Current assets divided by current liabilities.

Not enough comparable data to show this history.

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
2015-12-31	Current assets / current liabilities	Not reported	No source recorded
2016-12-31	Current assets / current liabilities	Not reported	No source recorded
2017-12-31	Current assets / current liabilities	Not reported	No source recorded

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2022 2022-01-01 – 2022-12-31	−Unit_Standard_USD_J14XWe-4AE6YifluMea2JA 557.52 million Exact value Exact value: -557517000 Unit_Standard_USD_J14XWe-4AE6YifluMea2JA 2022-01-01 – 2022-12-31: -557517000 Unit_Standard_USD_J14XWe-4AE6YifluMea2JA Inspect Net Income Open source Share or cite Citation for Net Income · Blueprint Medicines Corporation · 2022-12-31 Blueprint Medicines Corporation (edgar:1597264) Net Income: -557517000 Unit_Standard_USD_J14XWe-4AE6YifluMea2JA Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T13:49:12Z Snapshot: 4f0576df741ca9ce99a0a19b182da607af576553123ebb31b0ca4530075f302a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1597264/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=Unit_Standard_USD_J14XWe-4AE6YifluMea2JA&dimensions= Input fundies:NetIncome: -557517000 Unit_Standard_USD_J14XWe-4AE6YifluMea2JA (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1597264/000155837025000953/bpmc-20241231x10k.htm#3860649 Filing: 000155837025000953 The citation records this snapshot. The page link may show a newer release later.	−Unit_Standard_USD_J14XWe-4AE6YifluMea2JA 502.28 million Exact value Exact value: -502277000 Unit_Standard_USD_J14XWe-4AE6YifluMea2JA 2022-01-01 – 2022-12-31: -502277000 Unit_Standard_USD_J14XWe-4AE6YifluMea2JA Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Blueprint Medicines Corporation · 2022-12-31 Blueprint Medicines Corporation (edgar:1597264) Operating Cash Flow: -502277000 Unit_Standard_USD_J14XWe-4AE6YifluMea2JA Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T13:49:12Z Snapshot: 4f0576df741ca9ce99a0a19b182da607af576553123ebb31b0ca4530075f302a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1597264/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=Unit_Standard_USD_J14XWe-4AE6YifluMea2JA&dimensions= Input fundies:OperatingCashFlow: -502277000 Unit_Standard_USD_J14XWe-4AE6YifluMea2JA (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1597264/000155837025000953/bpmc-20241231x10k.htm#2336190 Filing: 000155837025000953 The citation records this snapshot. The page link may show a newer release later.	Unit_Standard_USD_J14XWe-4AE6YifluMea2JA 8.92 million Exact value Exact value: 8919000 Unit_Standard_USD_J14XWe-4AE6YifluMea2JA 2022-01-01 – 2022-12-31: 8919000 Unit_Standard_USD_J14XWe-4AE6YifluMea2JA Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Blueprint Medicines Corporation · 2022-12-31 Blueprint Medicines Corporation (edgar:1597264) Capital Expenditure: 8919000 Unit_Standard_USD_J14XWe-4AE6YifluMea2JA Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T13:49:12Z Snapshot: 4f0576df741ca9ce99a0a19b182da607af576553123ebb31b0ca4530075f302a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1597264/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=Unit_Standard_USD_J14XWe-4AE6YifluMea2JA&dimensions= Input fundies:CapitalExpenditure: 8919000 Unit_Standard_USD_J14XWe-4AE6YifluMea2JA (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1597264/000155837025000953/bpmc-20241231x10k.htm#2342194 Filing: 000155837025000953 The citation records this snapshot. The page link may show a newer release later.	−Unit_Standard_USD_J14XWe-4AE6YifluMea2JA 511.2 million Calculation and evidence -502277000 − 8919000 Unit_Standard_USD_J14XWe-4AE6YifluMea2JA Exact free cash flow: -511196000 Unit_Standard_USD_J14XWe-4AE6YifluMea2JA 2022-01-01 – 2022-12-31: -502277000 Unit_Standard_USD_J14XWe-4AE6YifluMea2JA · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 8919000 Unit_Standard_USD_J14XWe-4AE6YifluMea2JA · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Blueprint Medicines Corporation · 2022-12-31 Blueprint Medicines Corporation (edgar:1597264) Free cash flow: -511196000 Unit_Standard_USD_J14XWe-4AE6YifluMea2JA Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T13:49:12Z Snapshot: 4f0576df741ca9ce99a0a19b182da607af576553123ebb31b0ca4530075f302a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1597264?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -502277000 Unit_Standard_USD_J14XWe-4AE6YifluMea2JA (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1597264/000155837025000953/bpmc-20241231x10k.htm#2336190 Filing: 000155837025000953 Input fundies:CapitalExpenditure: 8919000 Unit_Standard_USD_J14XWe-4AE6YifluMea2JA (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1597264/000155837025000953/bpmc-20241231x10k.htm#2342194 Filing: 000155837025000953 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−Unit_Standard_USD_J14XWe-4AE6YifluMea2JA 506.98 million Exact value Exact value: -506984000 Unit_Standard_USD_J14XWe-4AE6YifluMea2JA 2023-01-01 – 2023-12-31: -506984000 Unit_Standard_USD_J14XWe-4AE6YifluMea2JA Inspect Net Income Open source Share or cite Citation for Net Income · Blueprint Medicines Corporation · 2023-12-31 Blueprint Medicines Corporation (edgar:1597264) Net Income: -506984000 Unit_Standard_USD_J14XWe-4AE6YifluMea2JA Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T13:49:12Z Snapshot: 4f0576df741ca9ce99a0a19b182da607af576553123ebb31b0ca4530075f302a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1597264/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=Unit_Standard_USD_J14XWe-4AE6YifluMea2JA&dimensions= Input fundies:NetIncome: -506984000 Unit_Standard_USD_J14XWe-4AE6YifluMea2JA (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1597264/000155837025000953/bpmc-20241231x10k.htm#3859554 Filing: 000155837025000953 The citation records this snapshot. The page link may show a newer release later.	−Unit_Standard_USD_J14XWe-4AE6YifluMea2JA 436.85 million Exact value Exact value: -436847000 Unit_Standard_USD_J14XWe-4AE6YifluMea2JA 2023-01-01 – 2023-12-31: -436847000 Unit_Standard_USD_J14XWe-4AE6YifluMea2JA Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Blueprint Medicines Corporation · 2023-12-31 Blueprint Medicines Corporation (edgar:1597264) Operating Cash Flow: -436847000 Unit_Standard_USD_J14XWe-4AE6YifluMea2JA Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T13:49:12Z Snapshot: 4f0576df741ca9ce99a0a19b182da607af576553123ebb31b0ca4530075f302a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1597264/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=Unit_Standard_USD_J14XWe-4AE6YifluMea2JA&dimensions= Input fundies:OperatingCashFlow: -436847000 Unit_Standard_USD_J14XWe-4AE6YifluMea2JA (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1597264/000155837025000953/bpmc-20241231x10k.htm#2335091 Filing: 000155837025000953 The citation records this snapshot. The page link may show a newer release later.	Unit_Standard_USD_J14XWe-4AE6YifluMea2JA 16.06 million Exact value Exact value: 16062000 Unit_Standard_USD_J14XWe-4AE6YifluMea2JA 2023-01-01 – 2023-12-31: 16062000 Unit_Standard_USD_J14XWe-4AE6YifluMea2JA Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Blueprint Medicines Corporation · 2023-12-31 Blueprint Medicines Corporation (edgar:1597264) Capital Expenditure: 16062000 Unit_Standard_USD_J14XWe-4AE6YifluMea2JA Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T13:49:12Z Snapshot: 4f0576df741ca9ce99a0a19b182da607af576553123ebb31b0ca4530075f302a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1597264/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=Unit_Standard_USD_J14XWe-4AE6YifluMea2JA&dimensions= Input fundies:CapitalExpenditure: 16062000 Unit_Standard_USD_J14XWe-4AE6YifluMea2JA (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1597264/000155837025000953/bpmc-20241231x10k.htm#2341105 Filing: 000155837025000953 The citation records this snapshot. The page link may show a newer release later.	−Unit_Standard_USD_J14XWe-4AE6YifluMea2JA 452.91 million Calculation and evidence -436847000 − 16062000 Unit_Standard_USD_J14XWe-4AE6YifluMea2JA Exact free cash flow: -452909000 Unit_Standard_USD_J14XWe-4AE6YifluMea2JA 2023-01-01 – 2023-12-31: -436847000 Unit_Standard_USD_J14XWe-4AE6YifluMea2JA · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 16062000 Unit_Standard_USD_J14XWe-4AE6YifluMea2JA · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Blueprint Medicines Corporation · 2023-12-31 Blueprint Medicines Corporation (edgar:1597264) Free cash flow: -452909000 Unit_Standard_USD_J14XWe-4AE6YifluMea2JA Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T13:49:12Z Snapshot: 4f0576df741ca9ce99a0a19b182da607af576553123ebb31b0ca4530075f302a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1597264?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -436847000 Unit_Standard_USD_J14XWe-4AE6YifluMea2JA (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1597264/000155837025000953/bpmc-20241231x10k.htm#2335091 Filing: 000155837025000953 Input fundies:CapitalExpenditure: 16062000 Unit_Standard_USD_J14XWe-4AE6YifluMea2JA (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1597264/000155837025000953/bpmc-20241231x10k.htm#2341105 Filing: 000155837025000953 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−Unit_Standard_USD_J14XWe-4AE6YifluMea2JA 67.09 million Exact value Exact value: -67089000 Unit_Standard_USD_J14XWe-4AE6YifluMea2JA 2024-01-01 – 2024-12-31: -67089000 Unit_Standard_USD_J14XWe-4AE6YifluMea2JA Inspect Net Income Open source Share or cite Citation for Net Income · Blueprint Medicines Corporation · 2024-12-31 Blueprint Medicines Corporation (edgar:1597264) Net Income: -67089000 Unit_Standard_USD_J14XWe-4AE6YifluMea2JA Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T13:49:12Z Snapshot: 4f0576df741ca9ce99a0a19b182da607af576553123ebb31b0ca4530075f302a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1597264/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=Unit_Standard_USD_J14XWe-4AE6YifluMea2JA&dimensions= Input fundies:NetIncome: -67089000 Unit_Standard_USD_J14XWe-4AE6YifluMea2JA (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1597264/000155837025000953/bpmc-20241231x10k.htm#3858477 Filing: 000155837025000953 The citation records this snapshot. The page link may show a newer release later.	−Unit_Standard_USD_J14XWe-4AE6YifluMea2JA 192.59 million Exact value Exact value: -192586000 Unit_Standard_USD_J14XWe-4AE6YifluMea2JA 2024-01-01 – 2024-12-31: -192586000 Unit_Standard_USD_J14XWe-4AE6YifluMea2JA Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Blueprint Medicines Corporation · 2024-12-31 Blueprint Medicines Corporation (edgar:1597264) Operating Cash Flow: -192586000 Unit_Standard_USD_J14XWe-4AE6YifluMea2JA Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T13:49:12Z Snapshot: 4f0576df741ca9ce99a0a19b182da607af576553123ebb31b0ca4530075f302a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1597264/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=Unit_Standard_USD_J14XWe-4AE6YifluMea2JA&dimensions= Input fundies:OperatingCashFlow: -192586000 Unit_Standard_USD_J14XWe-4AE6YifluMea2JA (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1597264/000155837025000953/bpmc-20241231x10k.htm#2333991 Filing: 000155837025000953 The citation records this snapshot. The page link may show a newer release later.	Unit_Standard_USD_J14XWe-4AE6YifluMea2JA 4.63 million Exact value Exact value: 4630000 Unit_Standard_USD_J14XWe-4AE6YifluMea2JA 2024-01-01 – 2024-12-31: 4630000 Unit_Standard_USD_J14XWe-4AE6YifluMea2JA Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Blueprint Medicines Corporation · 2024-12-31 Blueprint Medicines Corporation (edgar:1597264) Capital Expenditure: 4630000 Unit_Standard_USD_J14XWe-4AE6YifluMea2JA Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T13:49:12Z Snapshot: 4f0576df741ca9ce99a0a19b182da607af576553123ebb31b0ca4530075f302a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1597264/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=Unit_Standard_USD_J14XWe-4AE6YifluMea2JA&dimensions= Input fundies:CapitalExpenditure: 4630000 Unit_Standard_USD_J14XWe-4AE6YifluMea2JA (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1597264/000155837025000953/bpmc-20241231x10k.htm#2340016 Filing: 000155837025000953 The citation records this snapshot. The page link may show a newer release later.	−Unit_Standard_USD_J14XWe-4AE6YifluMea2JA 197.22 million Calculation and evidence -192586000 − 4630000 Unit_Standard_USD_J14XWe-4AE6YifluMea2JA Exact free cash flow: -197216000 Unit_Standard_USD_J14XWe-4AE6YifluMea2JA 2024-01-01 – 2024-12-31: -192586000 Unit_Standard_USD_J14XWe-4AE6YifluMea2JA · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 4630000 Unit_Standard_USD_J14XWe-4AE6YifluMea2JA · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Blueprint Medicines Corporation · 2024-12-31 Blueprint Medicines Corporation (edgar:1597264) Free cash flow: -197216000 Unit_Standard_USD_J14XWe-4AE6YifluMea2JA Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T13:49:12Z Snapshot: 4f0576df741ca9ce99a0a19b182da607af576553123ebb31b0ca4530075f302a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1597264?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -192586000 Unit_Standard_USD_J14XWe-4AE6YifluMea2JA (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1597264/000155837025000953/bpmc-20241231x10k.htm#2333991 Filing: 000155837025000953 Input fundies:CapitalExpenditure: 4630000 Unit_Standard_USD_J14XWe-4AE6YifluMea2JA (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1597264/000155837025000953/bpmc-20241231x10k.htm#2340016 Filing: 000155837025000953 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

170 filings · 4,381 latest values · 4,381 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001597264, 1597264, BPMC, edgar:1597264

Also known as BLUEPRINT MEDICINES CORPORATION, Blueprint Medicines Corp, Blueprint Medicines Corporation

Blueprint Medicines Corporation

Latest quarter

Revenue

Trailing twelve months

Revenue

Company performance

What changed year over year

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2017 2017-01-01 – 2017-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation